PAI‐1 gain‐of‐function genotype, factors increasing PAI‐1 levels, and airway obstruction: The GALA II Cohort
Summary Background PAI‐1 gain‐of‐function variants promote airway fibrosis and are associated with asthma and with worse lung function in subjects with asthma. Objective We sought to determine whether the association of a gain‐of‐function polymorphism in plasminogen activator inhibitor‐1 (PAI‐1) wit...
Saved in:
Published in | Clinical and experimental allergy Vol. 47; no. 9; pp. 1150 - 1158 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Wiley Subscription Services, Inc
01.09.2017
|
Subjects | |
Online Access | Get full text |
ISSN | 0954-7894 1365-2222 1365-2222 |
DOI | 10.1111/cea.12958 |
Cover
Summary: | Summary
Background
PAI‐1 gain‐of‐function variants promote airway fibrosis and are associated with asthma and with worse lung function in subjects with asthma.
Objective
We sought to determine whether the association of a gain‐of‐function polymorphism in plasminogen activator inhibitor‐1 (PAI‐1) with airway obstruction is modified by asthma status, and whether any genotype effect persists after accounting for common exposures that increase PAI‐1 level.
Methods
We studied 2070 Latino children (8‐21y) with genotypic and pulmonary function data from the GALA II cohort. We estimated the relationship of the PAI‐1 risk allele with FEV1/FVC by multivariate linear regression, stratified by asthma status. We examined the association of the polymorphism with asthma and airway obstruction within asthmatics via multivariate logistic regression. We replicated associations in the SAPPHIRE cohort of African Americans (n=1056). Secondary analysis included the effect of the at‐risk polymorphism on postbronchodilator lung function.
Results
There was an interaction between asthma status and the PAI‐1 polymorphism on FEV1/FVC (P=.03). The gain‐of‐function variants, genotypes (AA/AG), were associated with lower FEV1/FVC in subjects with asthma (β=−1.25, CI: −2.14,−0.35, P=.006), but not in controls. Subjects with asthma and the AA/AG genotypes had a 5% decrease in FEV1/FVC (P<.001). In asthmatics, the risk genotype (AA/AG) was associated with a 39% increase in risk of clinically relevant airway obstruction (OR=1.39, CI: 1.01, 1.92, P=.04). These associations persisted after exclusion of factors that increase PAI‐1 including tobacco exposure and obesity.
Conclusions and Clinical Relevance
The decrease in the FEV1/FVC ratio associated with the risk genotype was modified by asthma status. The genotype increased the odds of airway obstruction by 75% within asthmatics only. As exposures known to increase PAI‐1 levels did not mitigate this association, PAI‐1 may contribute to airway obstruction in the context of chronic asthmatic airway inflammation. |
---|---|
Bibliography: | Funding information Supported in part by the American Heart Association National Scientist Development Award and by the National Institutes of Health (K23 AI110731‐01 to SHC; R01‐ES015794, R01‐HL088133, R01‐HL078885, and R01‐HL104608, R01‐HL118267, R01‐AI077439, R01‐CA113710, R01‐AI079139); National Institute On Minority Health And Health Disparities of the National Institutes of Health under Award Number P60‐MD006902; the Flight Attendant Medical Research Institute (FAMRI), the Sandler Foundation (to E.G.B. and L.K.W.), the RWJF Amos Medical Faculty Development Award (to E.G.B.), and the American Asthma Foundation (to E.G.B. and L.K.W.). ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 These authors contributed equally to the manuscript. |
ISSN: | 0954-7894 1365-2222 1365-2222 |
DOI: | 10.1111/cea.12958 |